Abstract Little is known about the phenotypic changes that occur in vascular smooth muscle cells (SMCs) as the developing aorta undergoes the transition from a loosely organized, highly replicative tissue to a morphologically mature, quiescent tissue. In the present study, we have characterized the in vivo pattern of SMC replication during intrauterine and neonatal aortic development in the rat and have cultured and assessed the in vitro growth properties of embryonic, fetal, and neonatal vascular SMCs. Embryonic SMCs, which exhibited a very high in vivo replication rate (75% to 80% per day), demonstrated a significant potential for self-driven replication, as assessed by the ability to proliferate under serum-deprived conditions. Several lines of evidence suggest that the autonomous growth of SMCs in the "embryonic growth phenotype" may be driven by a unique mechanism independent of known adult SMC mitogens: embryonic SMC replication was not associated with the detectable secretion of mitogenic activity T nhe uninjured blood vessel wall is a remarkably quiescent tissue, with a vascular smooth muscle cell (SMC) replication index of <0.06% per day.1'2 Significant proliferation of SMCs occurs only during development, after transformation (a rare event), and after vascular injury. In the adult, unscheduled replication of SMCs is an important contributor to atherogenesis, the maintenance of hypertension (through vascular remodeling), and the restenosis of vascular grafts and angioplasties (reviewed in Schwartz et a13). Adult SMCs replicating after injury exhibit many features of "fetal" SMCs,4-8 suggesting that the expression of certain developmental phenotypes may contribute to vascular disease processes. Therefore, it seems critical to understand the various "growth phenotypes" expressed by SMCs throughout vascular development.
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We have begun to study, in a rat developmental model, the phenotypic changes that occur in vascular SMCs as the developing aorta undergoes the transition from a highly replicative to a fully quiescent tissue. We envision that multiple and probably redundant mechanisms, involving growth suppressor genes (reviewed in References 9 and 10), extracellular matrix molecules,11-13 cell-cell or cell-matrix adhesion molecules,14 growth inhibitory cytokines, [15] [16] [17] [18] 
Analytical Techniques
Northern analyses were performed essentially as previously described.23 cDNA probes used include a 500-bp EcoRIIHindIII fragment of a cDNA encoding bovine elastin24 and a 1.3-kb Pst I fragment of a cDNA encoding bovine actin (which recognizes a-, 8-, and y-actins). 25 Indirect immunofluorescence to detect a-smooth musclespecific actin was performed on methanol-permeabilized second-passage SMCs as previously described,26 using a monoclonal antibody specific for the SMC a-actin isoform. 22 
Results

Analysis of SMC Replication During Aortic Development In Vivo
BrdU immunocytochemistry was used to assess the replication rates of vascular SMCs throughout development in the rat. The injection protocol used ensured that the nuclei of all cells entering S phase in the 24 hours before death would be labeled with BrdU. Replication indexes were determined for the aortic arch, the thoracic aorta (proximal to the diaphragm), and the abdominal aorta (between the diaphragm and the renal arteries). Because no differences were noted among the data derived from the three sites for any given developmental age, the data were pooled for clarity of presentation (Fig 1) factors or matrix molecules from adjacent cell types or from the plasma), by an autogenous mechanism endogenous to the SMCs, or by a combination of such factors. To assess the contribution that autogenous mechanisms may play in driving the growth of SMCs during development, we isolated SMCs from the aortas of embryos at days e13, e14, e16, and e17, from fetuses at days elS to e21, and from neonates and adults at days 1, 7, 30, and 60. For comparison purposes, we also cultured embryonic adventitial fibroblasts, which exhibited a "swirling" pattern of growth, a spindle-shaped morphology, and a lack of serum-independent growth potential.
All of our SMC cultures (embryonic through adult) exhibited the "hill-and-valley" pattern of organization characteristic of adult SMCs (Fig 2) . SMC cultures exhibiting a "cobblestone" pattern of growth, as described for a subset of SMCs derived from neonatal rat aortas,20 were not observed in our studies; however, the explant methodologies used to derive our SMC cultures may not be optimal for the derivation of "epithelioid" SMCs. As a more rigorous test of the SMC nature of our embryonic and fetal cells, we examined the cells with respect to two additional markers known to be expressed in SMCs during early aortic development: elastin27 and a-smooth muscle actin.28 Total RNA was prepared from second-passage cultures and probed with cDNAs specific for elastin or actin. As shown in Fig 3, the SMC cultures were found to express significant levels of elastin and a-actin mRNAs. To verify that the a-actin message encoded smooth muscle-specific a-actin, we used immunofluorescence techniques to visualize the expression of this protein using a monoclonal antibody specific for the smooth muscle-specific actin isoform. As shown in Fig 4 , the cultures were uniformly composed of cells that stain positive for the presence of smooth muscle-specific a-actin. The combined presence of the hill-and-valley pattern of organization, a high level of expression of elastin mRNA, and the expression of the smooth muscle a-actin isoform verified that our cultures were of SMC origin.
To assess the capacity of the embryonic cells for The BrdU assay described previously (for Fig 5. middle and bottom panels) was used to determine the gestational age at which serum-independent growth capacity is lost during SMC development. The nuclearlabeling indexes of SMCs derived from animals of increasing developmental ages were determined after 72 hours in 0.1% fetal bovine serum. As presented in Fig 8, embryonic (days e13 to e17 ) and early fetal (day el8) SMCs maintained replication indexes of 28% to 33% in low serum; SMCs from animals fetal day e20 and older became largely growth arrested, with labeling indexes of 7% to 12%. Cell number experiments similar to those illustrated in the Fig 5 graph were repeated using SMCs derived from aortas at days e13, e14, e16, el,7 e18, e20, and e21 and postnatal days 1 and 60. The results were consistent with those shown in Fig 8: cells derived from the aortas of animals at days e13 to el8 showed significant serum-independent replication, whereas SMCs from fetal day e20 and older did not significantly replicate in culture under low-serum conditions. The data establish that the transition of aortic is characterized by a very high in vivo replication index and a significant capacity for serum-independent replication in vitro. This embryonic growth phenotype was found to be uniquely expressed by embryonic (days e13 to e17) and early fetal (day e18) SMCs in culture. The expression of this serum-independent phenotype does not appear to be associated with the secretion of a mitogen capable of stimulating adult SMCs. In experiments (not shown) using e17 SMCs, we were unable to detect significant autoactivation of PDGF, EGF, IGF, or FGF receptors, as assessed by the tyrosine phosphorylation of immunoisolated receptor proteins. The majority of SMC proliferation during aortic morphogenesis therefore appears to occur via a unique, as yet undefined, molecular mechanism. The data suggest that one factor contributing to the acquisition of quiescence in the adult blood vessel wall is the developmentally timed loss of this embryonic self-driven growth phenotype. Elucidation of the factors controlling the expression and loss of this phenotype should significantly advance our understanding of the mechanisms regulating vascular morphogenesis and SMC function during development and after vascular injury.
SMC Replication During Intrauterine Development In Vivo
A number of previous studies have addressed various aspects of aortic development in vivo. Morphological studies have shown that the basic structure of the rat aorta is largely developed by birth31 and that slow growth of the aorta continues postnatally.32-35 Owens and Thompson36 reported that the labeling index of aortic SMCs in newborn rats (after a single 1-hour labeling period) is -2% and that replication slowly decreases postnatally until adult replication levels are reached by 90 days. Because the available evidence suggested that the bulk of vascular SMC replication during development must occur before birth, we focused our studies on embryonic and fetal tissues and cells. The data reveal an extremely high (75% to 80% per day) replication index during embryonic life (through day e17) and a rapid transition to a significantly lower rate of proliferation by day e19. Our in vitro data suggest that the high SMC replication rate observed in the embryonic aorta is driven by mechanisms endogenous to eSMCs and that the reduction in aortic SMC replication rate at days e17 to e19 may result, at least in part, from the developmentally timed loss of this phenotype.
A Distinct Embryonic Growth Phenotype Expressed in Developing Vascular SMCs
The growth phenotype expressed by cultured embryonic and early fetal SMCs is primarily characterized by a significant ability for self-driven replication in serum-free conditions. This characteristic is not significantly expressed by cells derived from adult aortas; our data suggest that the loss of this phenotype occurs during early fetal life, between days e18 and e20. Because the self-driven replication of eSMCs does not appear to be associated with the secretion of known mitogens for adult SMCs, the most likely explanation for our data is that eSMCs replicate in response to a novel embryo-specific mitogen whose receptor is not expressed in adult SMCs. Alternately, a completely intracellular, growth factorindependent growth stimulus might drive e17 proliferation. Studies are ongoing to determine the molecular mechanisms responsible for the self-driven growth of eSMCs and the changes in gene expression that underlie the loss of serum-independent growth potential. Of particular interest will be the elucidation of the timing mechanism that controls the conversion of SMCs from the embryonic to the adult growth phenotype.
On the basis of our in vitro mitogenesis assays, the replication of eSMCs does not appear to be markedly affected by a variety of exogenously added growth factors (Fig 7) 
